Prostate Cancer Diagnostics Market Research Report to Reach US$ 284 Million by the End of the Forecast Period 2017-2022

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for prostate cancer. Rising number of deaths caused by prostate cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of prostate cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of prostate cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

Key players in the Global Prostate Cancer Diagnostics Market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on prostate cancer patients. Such cooperative efforts are of paramount importance in the global prostate cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Download Free Sample Report Here – https://www.factmr.com/connectus/sample?flag=S&rep_id=58

Uncontrollable growth of cells in prostate gland leads to the development of prostate cancer. Several men develop low-grade prostatic intraepithelial neoplasia (PIN), however they don’t necessarily develop prostate cancer. No sure way has been found to prevent prostate cancer, however the chances can be lowered by being physically active and maintaining a healthy weight.

An increasing geriatric population across the developed world along with access to top-quality healthcare is expected to benefit the prostate cancer diagnostics market. Healthcare spending is growing by leaps and bounds both though the government as well as private providers. As per the WHO Health Spending Observatory, the spending on health may rise to US$ 18.2 trillion by the year 2040 with annual growth rates of 3.4% in upper middle income countries and 2.7% in high-income ones. The global prostate cancer diagnostics market is projected to grow to nearly US$ 1.1 billion in 2022.

The PCA3 and PSA test segments can be considered the most important in the prostate cancer diagnostics market as they both represent the highest potential in terms of market opportunity. The PSA segment is anticipated to be worth just over US$ 270 million in 2017 and it should grow at a healthy CAGR during the period 2017-2022. On the other hand, the PCA3 segment is poised to grow to nearly US$ 284 million by the end of the forecast period.

North America is the largest region for both segments and accounts for nearly 2/5th of the prostate cancer diagnostics market. The region’s large geriatric population and high prevalence of cancer mean that demand for prostate cancer diagnostics will continue to remain strong during the forecast period.

Check Complete Report Here – https://www.factmr.com/report/58/prostate-cancer-diagnostics-market

The immunohistochemistry segment is projected to witness a CAGR of 4.5% for the five-year study period. While North America may be the largest regional contributor, key stakeholders could also focus on Europe as it holds a revenue share of more than 30% throughout the period.

Focus on Hospital Labs and Research Institutes

The hospital associated labs segment is assessed to grow significantly during the forecast period. It would make sense for companies to focus on cancer research institutes as collaboration can help in the development of innovative solutions. In this case, companies could think of targeting the APEJ region as it has the highest CAGR during the forecast period. The region spends much less on healthcare as a percentage of GDP than the developed world but strong economic growth will all but ensure that it becomes ever-more important to regional governments in future.

Competition Tracking

Key players in the global market for prostate cancer diagnostics include Abbott Laboratories, Biocept, Inc., AstraZeneca plc. Cancer Genetics, Inc., Danaher Corporation, Bayer Aktiengesellschaft, Becton, Dickinson and Company, Agilent Technologies, Foundation Medicine, Inc., and Myriad Genetics Inc.

Table of Contents

Chapter 1. Global Prostate Cancer Diagnostics Market – Executive Summary. 11

Chapter 2. Global Prostate Cancer Diagnostics Market Overview. 13

2.1. Introduction. 13

2.1.1. Global Prostate Cancer Diagnostics Market Taxonomy. 13

2.1.2. Global Prostate Cancer Diagnostics Market Definition. 13

2.2. Global Prostate Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 14

2.2.1. Global Prostate Cancer Diagnostics Market Y-o-Y Growth. 14

2.3. Global Prostate Cancer Diagnostics Market Dynamics. 14

2.3.1. Drivers. 14

2.3.2. Restraints. 14

2.3.3. Trends. 15

2.4. Supply Chain. 15

2.5. Epidemiology. 15

2.6. Key Participants Market Presence (Intensity Map) By Region. 15

Chapter 3. Global Prostate Cancer Diagnostics Market Analysis and Forecast By Test Type. 16

3.1. Global Prostate Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 16

3.1.1. PSA Tests Prostate Cancer Diagnostics Market Size and Forecast, 2012-2022. 16

3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 16

3.1.1.2. Market Share Comparison, By Region. 18

3.1.1.3. Y-o-Y growth Comparison, By Region. 18

3.1.2. CTC Tests Prostate Cancer Diagnostics Market Size and Forecast, 2012-2022. 19

3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 19

3.1.2.2. Market Share Comparison, By Region. 21

3.1.2.3. Y-o-Y growth Comparison, By Region. 21

Continued……………………….

Order a copy of Global Market Research Report Here – https://www.factmr.com/checkout/58/S

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us –

FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/